OTLK Stock Surges After FDA Ends Decade-Long Wait For Ophthalmic Bevacizumab

FDA approved LYTENAVA, the first bevacizumab specifically for eye injections.

LYTENAVA treats wet age-related macular degeneration.

Approval ends a decade-long wait for an ophthalmic version of bevacizumab.

OTLK stock surged following the FDA decision.